Chorokbaem Healthcare Co Ltd (118000) - Net Assets
Based on the latest financial reports, Chorokbaem Healthcare Co Ltd (118000) has net assets worth ₩120.98 Billion KRW (≈ $81.99 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩197.96 Billion ≈ $134.16 Million USD) and total liabilities (₩76.98 Billion ≈ $52.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 118000 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩120.98 Billion |
| % of Total Assets | 61.11% |
| Annual Growth Rate | 18.34% |
| 5-Year Change | 1.32% |
| 10-Year Change | 800.4% |
| Growth Volatility | 52.55 |
Chorokbaem Healthcare Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Chorokbaem Healthcare Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Chorokbaem Healthcare Co Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Chorokbaem Healthcare Co Ltd (2013–2025)
The table below shows the annual net assets of Chorokbaem Healthcare Co Ltd from 2013 to 2025. For live valuation and market cap data, see 118000 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩120.98 Billion ≈ $81.99 Million |
+3.58% |
| 2024-12-31 | ₩116.80 Billion ≈ $79.15 Million |
-15.18% |
| 2023-12-31 | ₩137.70 Billion ≈ $93.32 Million |
+6.27% |
| 2022-12-31 | ₩129.58 Billion ≈ $87.81 Million |
+8.53% |
| 2021-12-31 | ₩119.40 Billion ≈ $80.92 Million |
+56.85% |
| 2020-12-31 | ₩76.13 Billion ≈ $51.59 Million |
+111.84% |
| 2019-12-31 | ₩35.94 Billion ≈ $24.35 Million |
+94.13% |
| 2018-12-31 | ₩18.51 Billion ≈ $12.54 Million |
-1.06% |
| 2017-12-31 | ₩18.71 Billion ≈ $12.68 Million |
+39.25% |
| 2016-12-31 | ₩13.44 Billion ≈ $9.11 Million |
+117.22% |
| 2015-12-31 | ₩6.19 Billion ≈ $4.19 Million |
-25.61% |
| 2014-12-31 | ₩8.32 Billion ≈ $5.64 Million |
-48.17% |
| 2013-12-31 | ₩16.04 Billion ≈ $10.87 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chorokbaem Healthcare Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34810.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩190.73 Billion | 159.71% |
| Total Equity | ₩119.42 Billion | 100.00% |
Chorokbaem Healthcare Co Ltd Competitors by Market Cap
The table below lists competitors of Chorokbaem Healthcare Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cogelec SA
PA:ALLEC
|
$242.29 Million |
|
Daehan Steel
KO:084010
|
$242.50 Million |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
$242.59 Million |
|
GoldMining Inc
TO:GOLD
|
$242.77 Million |
|
Silver Storm Mining Ltd.
V:SVRS
|
$242.03 Million |
|
Mitrabahtera Segara Sejati Tbk
JK:MBSS
|
$242.01 Million |
|
Vine Hill Capital Investment Corp. Class A Ordinary Shares
NASDAQ:VCIC
|
$242.00 Million |
|
Roman DBDR Acquisition Corp. II Ordinary shares
NASDAQ:DRDB
|
$241.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chorokbaem Healthcare Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 116,798,139,380 to 119,421,169,810, a change of 2,623,030,430 (2.2%).
- Net income of 498,242,840 contributed positively to equity growth.
- New share issuances of 3,500,000,000 increased equity.
- Other factors decreased equity by 1,375,212,410.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩498.24 Million | +0.42% |
| Share Issuances | ₩3.50 Billion | +2.93% |
| Other Changes | ₩-1.38 Billion | -1.15% |
| Total Change | ₩- | 2.25% |
Book Value vs Market Value Analysis
This analysis compares Chorokbaem Healthcare Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.99x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.73x to 2.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩762.84 | ₩2080.00 | x |
| 2018-12-31 | ₩671.89 | ₩2080.00 | x |
| 2019-12-31 | ₩905.02 | ₩2080.00 | x |
| 2020-12-31 | ₩1339.26 | ₩2080.00 | x |
| 2021-12-31 | ₩1468.26 | ₩2080.00 | x |
| 2022-12-31 | ₩1171.64 | ₩2080.00 | x |
| 2023-12-31 | ₩862.11 | ₩2080.00 | x |
| 2024-12-31 | ₩708.83 | ₩2080.00 | x |
| 2025-12-31 | ₩695.22 | ₩2080.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chorokbaem Healthcare Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.52%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.66x
- Recent ROE (0.42%) is above the historical average (-34.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -29.06% | -36.60% | 0.57x | 1.40x | ₩-6.13 Billion |
| 2014 | -108.35% | -75.21% | 0.60x | 2.41x | ₩-9.66 Billion |
| 2015 | -122.77% | -66.32% | 0.70x | 2.65x | ₩-8.21 Billion |
| 2016 | -64.16% | -76.75% | 0.39x | 2.15x | ₩-9.96 Billion |
| 2017 | -15.70% | -7.89% | 1.00x | 1.98x | ₩-4.76 Billion |
| 2018 | -65.48% | -34.93% | 0.56x | 3.34x | ₩-13.88 Billion |
| 2019 | -13.41% | -8.55% | 0.80x | 1.95x | ₩-8.38 Billion |
| 2020 | 14.80% | 41.84% | 0.19x | 1.82x | ₩3.65 Billion |
| 2021 | 6.48% | 41.58% | 0.11x | 1.48x | ₩-4.20 Billion |
| 2022 | -49.93% | -259.47% | 0.10x | 1.91x | ₩-59.48 Billion |
| 2023 | -13.73% | -84.26% | 0.11x | 1.47x | ₩-25.13 Billion |
| 2024 | 7.27% | 42.05% | 0.13x | 1.35x | ₩-3.18 Billion |
| 2025 | 0.42% | 1.52% | 0.17x | 1.66x | ₩-11.44 Billion |
Industry Comparison
This section compares Chorokbaem Healthcare Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $117,567,307,285
- Average return on equity (ROE) among peers: 3.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chorokbaem Healthcare Co Ltd (118000) | ₩120.98 Billion | -29.06% | 0.64x | $242.13 Million |
| PharmGen Science Inc (004720) | $228.21 Billion | 2.67% | 0.47x | $61.63 Million |
| Korean Drug Co. Ltd (014570) | $65.05 Billion | 5.99% | 0.17x | $30.25 Million |
| BCWORLD PHARM. Co. Ltd (200780) | $79.55 Billion | 0.35% | 1.30x | $30.55 Million |
| Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) | $97.46 Billion | 4.95% | 1.31x | $131.08 Million |
About Chorokbaem Healthcare Co Ltd
METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd. in August 2024. METACARE CO., Ltd. was founde… Read more